Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2007

View Archived Issues

SASP technology: a novel approach to treat bacterial infections

MenACWY-TT meningococcal vaccine immunogenic in children

In vitro studies reveal antibacterial activity of novel carbapenem ME-1036

Sitafloxacin demonstrates efficacy against urinary tract infection pathogens

New antidiabetic agents disclosed in recent patents

Novel antiinfective agents disclosed in recent patent literature

Prexige withdrawn from Canadian market

Lilly advances atomoxetine to phase II for adult ADHD in Japan

Aptivus receives full FDA approval as part of combination therapy for HIV

Genesis to continue to use MorphoSys' HuCAL-based antibodies for drug discovery

GSK seeks prequalification for Cervarix from the WHO

Interim analysis complete in pivotal pafuramidine trial for African sleeping sickness

Phase I study commences for topical diclofenac sodium patch

Top-line results reported for granulated mesalamine in ulcerative colitis

TopoTarget and Lundbeck sign agreement for siramesine

Wyeth acquires biopharmaceutical company Haptogen

Ixabepilone improves progression-free survival in phase III metastatic breast cancer study

HI-164 vaccine reduces hospitalizations in COPD patients

Ki-26894 shows potential for the treatment of gastric cancer in vivo

EpiCept successfully completes phase I with novel small-molecule VDA

Avontec advances AVT-02 UE into the clinic for inflammatory skin diseases

Positive phase IIb data reported for BHT-3009 in multiple sclerosis

Loss of T-bet function leads to a communicable form of ulcerative colitis in mice / News in Context

Positive interim data reported for PRX-302

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...